Toxicity Management and Quality of Life Considerations for Patients with HER2-Positive Metastatic Breast Cancer

Dr. Kruse addresses the balance between efficacy and quality of life when using T-DXd in earlier treatment lines and prolonged therapy contexts. Proactive nausea management becomes crucial given extended treatment durations, requiring multi-agent antiemetic regimens rather than single-drug approaches.

She emphasizes olanzapine's utility at bedtime for managing nausea while addressing concurrent symptoms including sleep disruption, anxiety, and poor appetite common in metastatic breast cancer. The drug's multiple benefits make it particularly valuable for comprehensive symptom management.

Dose reduction represents a powerful tool for managing cumulative fatigue while maintaining cancer control efficacy. This requires reinforcing with patients that dose reduction doesn't compromise treatment effectiveness, particularly important as patients may underreport toxicities when experiencing good responses.

Dr. Rao distinguishes toxicity management approaches between metastatic and adjuvant settings. In adjuvant treatment, patients can better tolerate temporary toxicities knowing treatment has defined endpoints (4 or 14 cycles), making nausea and fatigue more acceptable.

The critical consideration in adjuvant settings involves balancing ILD risk with curative intent. DESTINY-Breast11 data showing less than 5% ILD risk with 4 cycles was reassuring, though DESTINY-Breast05's 14-cycle regimen showed rates consistent with metastatic experience (slightly over 10%).

Both panelists emphasize that moving T-DXd into earlier treatment lines requires more stringent monitoring compared to second-line metastatic use, where patients lack superior alternatives. Earlier-line use necessitates careful risk-benefit assessment against previously effective standard treatments.

The panel notes that although previous maintenance THP regimens were well-tolerated, T-DXd's extended use requires dedicated attention to toxicity management strategies not previously necessary in HER2-positive treatment paradigms.